A Method for Multiplexed Measurement of Mitochondrial Pyruvate Carrier Activity*

Lawrence R. Gray¹, Adam J. Rauckhorst¹, and Eric B. Taylor²
From the Department of Biochemistry, the Fraternal Order of the Eagles Diabetes Research Center, the Abboud Cardiovascular Research Center, and the Pappajohn Biomedical Institute, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242

The discovery that the MPC1 and MPC2 genes encode the protein components of the mitochondrial pyruvate carrier (MPC) has invigorated studies of mitochondrial pyruvate transport and its regulation in normal and disease states. Indeed, recent reports have demonstrated MPC involvement in the control of cell fate in cancer and gluconeogenesis in models of type 2 diabetes. Biochemical measurements of MPC activity are foundational for understanding the role of pyruvate transport in health and disease. We developed a 96-well scaled method of [¹⁴C]pyruvate uptake that markedly decreases sample requirements and increases throughput relative to previous techniques. This method was applied to determine the mouse liver MPC $K_m$ (28.0 ± 3.9 μM) and $V_{\text{max}}$ (1.08 ± 0.05 nmol/min/mg), which have not previously been reported. $K_m$ and $V_{\text{max}}$ of the rat liver MPC were found to be 71.2 ± 17 μM and 1.42 ± 0.14 nmol/min/mg, respectively. Additionally, we performed parallel pyruvate uptake and oxidation experiments with the same biological samples and show differential results in response to fasting, demonstrating the continued importance of a direct MPC activity assay. We expect this method will be of value for understanding the contribution of the MPC activity to health and disease states where pyruvate metabolism is expected to play a prominent role.

Pyruvate is a central metabolite linking cytoplasmic and mitochondrial metabolism. In the cytosol, pyruvate is generated as the terminal product of glycolysis, from amino acid interconversions and transamination reactions, and from oxidation of lactate. After transport across the mitochondrial inner membrane, pyruvate is converted to acetyl-CoA or oxaloacetate through the respective activities of pyruvate dehydrogenase or pyruvate carboxylase. Acetyl-CoA provides carbon for the tricarboxylic acid cycle, whereas oxaloacetate may be shunted toward either the tricarboxylic acid cycle or gluconeogenesis, depending upon prevailing metabolic demands. The critical protein complex linking these cytosolic and mitochondrial processes is the mitochondrial pyruvate carrier (MPC),³ which imports pyruvate across the mitochondrial inner membrane barrier into the matrix. Although a distinct, biochemically inhibitable MPC activity was identified over four decades ago, the genes encoding the MPC have only recently been identified (1, 2).

The MPC is an orphan carrier that is distantly related to the SemiSWEET family of bacterial transporters rather than the canonical SLC25A family of mitochondrial solute carriers (3, 4). The MPC complex comprises two paralogous subunits, MPC1 and MPC2. The stoichiometry of these subunits has yet to be determined but is potentially dynamic (5). MPC1 is ~12 kDa with two predicted transmembrane domains. MPC2 is slightly larger at 14 kDa and contains three predicted transmembrane domains (6). Loss of either MPC1 or MPC2 protein results in the destabilization and degradation of the other and thus loss of the MPC complex (7, 8).

More recent investigations have demonstrated that the MPC may be a point of altered metabolic regulation in disease states such as cancer, obesity, and type 2 diabetes (6–11). Hepatic Mpc1 transcript and MPC1 and MPC2 protein levels are increased in the high fat diet-induced obesity mouse model of type 2 diabetes; this could contribute to increased gluconeogenic carbon flux (7, 8). In contrast, loss of MPC activity in models of cancer promotes a Warburg-like metabolism with increased glutamine utilization that could contribute to oncogenic transformation (9–11). The MPC proteins may also be covalently regulated by post-translational modifications. Mitochondrial proteome screens have identified several post-translational modifications to MPC1 and MPC2 in response to fasting and a high fat-fed mouse model of diabetes (12, 13). However, the effects of these modifications on MPC function have not been determined. Given the central metabolic node occupied by the MPC, changes in MPC activity, either through post-translational modifications or protein abundance, may profoundly regulate overall cellular metabolism.

Several methods have been developed to measure the MPC-specific activity. For each of these methods, mitochondria are incubated in a buffer containing radiolabeled pyruvate. Over time, the MPC transports pyruvate into the matrix until that assayed is stopped. Each method quantifies mitochondrial

---

¹ Both authors contributed equally to this work.

² To whom correspondence should be addressed: Carver College of Medicine, University of Iowa, 169 Newton Rd., 3316 Pappajohn Biomedical Research Bldg., Iowa City, IA 52242. E-mail: eric-taylor@uiowa.edu.

³ The abbreviations used are: MPC, mitochondrial pyruvate carrier; TMPD, N,N,N’,N’-tetramethyl-p-phenylenediamine dihydrochloride; MIB, mitochondrial isolation buffer; UB, uptake buffer; CHC, α-cyano-4-hydroxycinnamic acid; FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone.
matrix-localized radiolabeled pyruvate using a scintillation counter for calculation of a relative MPC specific activity. The chief difference among these methods is how mitochondrial pyruvate uptake is halted. Techniques that have been used for halting uptake include centrifugation to pellet the mitochondria (14, 15), filtration through a membrane to separate mitochondria and uptake buffer (16), and a rapid density gradient separation (17). However, the gold standard method is the inhibitor stop technique (15, 18), which utilizes specific MPC chemical inhibitors like UK5099 and α-cyano-4-hydroxycinnamic acid (CHC) to halt mitochondrial pyruvate uptake.

There are significant advantages of halting uptake using the inhibitor stop approach. Inhibitors terminate uptake on a much faster time scale compared with centrifugation or filtration techniques, allowing for resolved capture of kinetic information. In addition, the use of inhibitors in wash buffers after stopping uptake prevents export of matrix pyruvate. However, despite these technical strengths of the inhibitor stop method, it has been labor- and sample-intensive. Milligram amounts of mitochondria per time point have been required. Previous kinetic studies have been applied to model systems such as rat liver where large amounts of mitochondria are easily obtained (18). With the prevalence of transgenic mouse models and cell culture systems where raw material is more limited, a more efficient method is required for practical measurements of MPC activity.

We report the development of a 96-well scaled mitochondrial pyruvate uptake assay for multiplexed measurement of the MPC specific activity. Our method requires decreased amounts of mitochondrial sample and markedly decreased assay time per sample and greatly increases overall throughput. We demonstrate the utility of this method by determining the kinetics of the mouse liver MPC specific activity.

**Experimental Procedures**

**Animal Care**—All animal experiments were conducted in accordance with the University of Iowa Animal Use and Care Committee. Mouse experiments were performed with 11–14-week-old C57 Bl6/J male mice purchased from The Jackson Laboratory (catalog number 000664). Rat experiments were performed with Sprague-Dewey rats purchased at a weight of 275–300 g from Harlan Laboratories (catalog number 211M).

**Buffers**—The following buffers were used in this protocol. Mitochondrial isolation buffer (MIB) contained 70 mM sucrose, 210 mM D-mannitol, 5 mM HEPS, pH 7.4, 1 mM EGTA, and 0.5% fatty acid-free bovine serum albumin (Sigma, catalog number A3803). Uptake buffer (UB) contained 120 mM KCl, 5 mM HEPS, pH 7.4, 1 mM EGTA, 2 μM rotenone, and 2 μM antimycin A. 2× PYR buffer contained 120 mM KCl, 5 mM HEPS, pH 6.1, 1 mM EGTA, 2 μM rotenone, 2 μM antimycin A, and 0.0020–0.4000 mM [2-14C]pyruvate as noted. Stop buffer contained 108 mM KCl, 4.5 mM HEPS, pH 6.8, 0.9 mM EGTA, 1.8 μM rotenone, 1.8 μM antimycin A, and 10 mM CHC (Sigma, catalog number 476870) (nine parts UB, pH 6.8, and one part 100 mM CHC). Wash buffer contained uptake buffer, pH 6.8, supplemented with 2 mM CHC and 10 mM pyruvate. Clark buffer contained 70 mM sucrose, 210 mM D-mannitol, 10 mM KH2PO4, 5 mM MgCl2, 5 mM HEPS, pH 7.4, 1 mM EGTA, 0.2% fatty acid-free BSA, 5 mM succinate, pH 7.4, and 2 μM rotenone. Mitochondrial Seahorse buffer contained 70 mM sucrose, 210 mM D-mannitol, 10 mM KH2PO4, 5 mM MgCl2, 5 mM HEPS, pH 7.4, 1 mM EGTA, and 0.2% fatty acid-free BSA.

**Mitochondrial Isolation**—Mitochondria were isolated as described previously by Rogers et al. (19) and as summarized in Fig. 1. Mice and rats were anesthetized by isoflurane inhalation and sacrificed via cervical dislocation or thoracotomy, respectively. Each liver was washed first in ice-cold PBS and second in ice-cold MIB. Livers, ~1.0 g (mouse) or ~13.0 g (rat) of wet tissue, were finely minced in 10 volumes of fresh MIB and homogenized in four passes of a motor rotated at 400–500 rpm using a Teflon-on-glasm homogenizer. The homogenate was transferred to 50-ml tubes and centrifuged at 800 × g for 10 min at 4 °C (800 × g spin). The pellet was discarded, and the 800 × g supernatant was transferred to a polycarbonate tube and centrifuged at 8000 × g for 10 min (8000 × g spin). The 8000 × g pellet was resuspended in a similar volume of fresh MIB. If pyruvate oxidation assays were conducted in parallel, 2–3 × 0.3-ml aliquots of resuspended mitochondria were placed into 1.5-ml tubes and centrifuged at 9000 × g for 10 min at 4 °C. The supernatant was removed, and the pellet was kept on ice until resuspension and dispersal into assay vessels. For measuring mitochondrial pyruvate uptake, the remaining resuspended 8000 × g pellet was centrifuged at 9000 × g for 10 min at 4 °C. The 9000 × g pellet was resuspended in 1.10 ml of MIB and split into 1.0- and 0.1-ml aliquots in 1.5-ml tubes. These tubes were centrifuged at 9000 × g for 10 min at 4 °C. The supernatant was removed, and the pellets were kept on ice. The 0.10-ml pellet was diluted into 300 μl of PBS and used for Bradford assays (20) using the Bio-Rad Protein Assay Dye Reagent (catalog number 500-0006) prior to uptake assays to guide dilution of the 1.0-ml pellet for mitochondrial pyruvate uptake assays.

**Multiplexed Mitochondrial Pyruvate Uptake**—Mitochondria for measuring uptake were kept as pellets on ice until analysis. Mitochondria were resuspended to ~15.0 mg/ml in UB. The mitochondria were split into two equal volumes, one of which was treated with the MPC inhibitor CHC to a final concentration of 2 μM as a negative control and the other remaining in an equal volume of untreated UB. The mitochondria were incubated on ice for 5 min. Typically, each mitochondrial preparation was assayed for pyruvate uptake in quadruple technical replicates. Therefore, ~80 μl each of untreated and CHC-pre-treated mitochondria were placed into 8 wells of a standard 96-well plate, alternating treatment conditions. To start the pyruvate uptake assay, an equal volume of mitochondria (65 μl) was added and mixed with an equal volume of 2× PYR buffer. This mixing of the UB mitochondrial preparations with the 2× PYR buffer yielded a final buffer with a pH of 6.8. Samples were taken at 5, 10, 20, and 30 s after the start of the assay. For each time point, to stop the assay, 30 μl of the uptake reaction was withdrawn from the reaction well and mixed with 70 μl of stop buffer in another well. After stopping the reaction, the mitochondria were separated from the reaction mixture using a 96-well vacuum manifold (Whatman Manifold I Spot Blot, catalog number 10447850). Efficiency of the assay is improved when two individuals work together with one person preparing the blot apparatus (see below) and performing the assay and the
second person trimming and processing the filters for data collection.

Vacuum Manifold Setup—Prior to the assay, manifold wells not to be used were sealed using 96-well plate sealers on both the top and bottom of the filter support plate as shown in Fig. 2A. For setup, the manifold was oriented with the filter support plate being placed upon the vacuum plenum with the vacuum line adapter facing toward the back. First, a piece of chromatography paper trimmed to \(~4 \times 3\) inches (Whatman, catalog number 3030-6461) was wetted in wash buffer and placed atop the filter support. Second, a piece of plastic or Parafilm was placed over the top of the filters. This piece was cut like the plate sealers so that the inactive wells were blocked whereas the active wells were unobstructed. Third, a one-piece layer of 0.45-\(\mu\)m nitrocellulose membrane, also prematted in wash buffer, was added. Fourth, a piece of 0.80-\(\mu\)m mixed cellulose ester filter (MF-Millipore, catalog number AAWP14250 or AAWP09000) was placed atop the 0.45-\(\mu\)m nitrocellulose membrane. A finger was run across the filters to eliminate air bubbles. Fifth, the sample well plate of the manifold apparatus was placed on top, and the manifold was clamped shut. Finally, Parafilm was stretched and wrapped around the entire apparatus in at least two layers as an extra safeguard against inward air leaks (see Fig. 2B). The layering of membranes, filters, and manifold is illustrated in Fig. 2C. The final prepared apparatus was connected to a vacuum source and placed \(~\frac{3}{2}\) deep into wetted iced. Prior to assays, to confirm the patency of the seal and ensure all wells drained correctly, 100 \(\mu\)l of water or wash buffer was passed through each well with the vacuum. If any well did not drain correctly, the entire apparatus was disassembled and prepared again. The underlying chromatography filter paper was replaced after each assay.

Multiplexed Washing and Separation of Postassay Mitochondria—With the vacuum on (\(~15\) p.s.i.) and connected to the manifold apparatus assembled as described in the foregoing section and using a multichannel pipette, reaction mixtures from the 96-well plate (as shown in Fig. 2D) were transferred to the manifold. After every well in a row had drained, 200 \(\mu\)l of wash buffer was added and allowed to drain. This wash step was performed two to three times and results in mitochondria in each well being deposited on the ester layer in small discs. After all of the wells had drained, the manifold was removed from the vacuum line, and the Parafilm was removed. From this point in the assay, the ester and nitrocellulose filter layers were treated as a single layer as illustrated in Fig. 2E. This dual filter layer was cut into small squares for each mitochondrial disc as illustrated in Fig. 2F. Each sample was then individually placed into 7-ml Seahorse buffer. Mitochondria—

Clark Electrode Studies—Oxygen consumption was determined using a Clark-type electrode. In brief, mitochondria were diluted to 0.5 mg/ml into Clark buffer. Once a basal respiration rate was achieved, rates of State III and State IV + oligomycin respiration were determined after the addition ADP to a final concentration of 100 \(\mu\)M and the successive addition of 1 \(\mu\)M oligomycin, respectively. Next, 0.2 \(\mu\)M FCCP was added to induce an uncoupled rate of oxygen consumption. Finally, 1 \(\mu\)M antimycin A was added to prevent electron transfer at Complex III and eliminate succinate-driven respiration. Each addition was made once a constant rate of respiration was achieved. The respiratory control ratio was determined as the State III rate/State IV + oligomycin rate.

High Resolution Respirometry Measurements—Pyruvate oxidation respirometry experiments were carried out essentially as described previously (19). A Seahorse Bioscience XF96 extracellular flux analyzer was used for all experiments. Briefly, aliquots of mitochondria were resuspended in 100 \(\mu\)l of mitochondrial Seahorse buffer. Mitochondrial protein concentration was measured using the Bio-Rad Protein Assay Dye Reagent, and samples were diluted to 0.25 mg/ml in mitochondrial Seahorse buffer. 20 \(\mu\)l of diluted mitochondria, for 5 \(\mu\)g of total mitochondrial protein, was loaded into V3-PET Seahorse plates and centrifuged at 2000 \(\times\) \(g\) for 20 min. 160 \(\mu\)l of mitochondrial Seahorse buffer with 2.81 \(\text{mm}\) pyruvate + 0.28 \(\text{mm}\) malate was added to each well such that the final substrate concentration was 2.5 \(\text{mm}\) pyruvate + 0.25 \(\text{mm}\) malate. A three-injection protocol was performed. Triplicate measurements were performed after each injection, and each measurement consisted of a 1-min mixing step, a 1-min wait step, and a 3-min measurement step. First, basal oxygen consumption was measured. Second, oxygen consumption was stimulated with a combination of 4 \(\text{mm}\) ADP and 1 \(\mu\)M FCCP. Third, MPC specific activity was inhibited by 1 \(\mu\)M CHC. Finally, Complex I activity was inhibited by 1 \(\mu\)M rotenone.

Western Blotting—Standard Western blotting and SDS-PAGE methods were used. Briefly, samples were separated using either a 10 or 20% separating gel with a 4% stacking gel for 20 min at 100 V followed by 60 min at 200 V. Proteins were transferred to 0.2-\(\mu\)m nitrocellulose membrane (Amersham Biosciences, Protran, catalog number 10600001) at 100 V for 60 min. Blots were blocked for 1 h with 5% milk in TBS and incubated in primary antibody in 5% milk in TBS-Tween 20 overnight. Antibodies were used at the following concentrations: anti-VDAC, 1:1000 (Cell Signaling Technology, catalog number 4661S); anti-calreticulin, 1:1000 (Cell Signaling Technology, catalog number 2891S); anti-HSP90, 1:1000 (Cell Signaling Technology, catalog number 4874S); anti-pyruvate dehydrogenase, 1:1000 (Cell Signaling Technology, catalog number 3205S); and anti-MPC1, 1:1000 (a generous gift from Dr. Brian Finck). Blots were visualized using a LI-COR Odyssey CLx imager and a goat anti-rabbit DyLight 800 secondary antibody (1:5000; Thermo, catalog number SA5-35571).

Data Analysis and Statistics—The MPC specific activity was defined as activity of the non-CHC-treated samples less the
activity of the CHC-treated samples (18). Specific activity relative to CPM was determined for each experiment by counting 10 μl of 2× PYR buffer and thus a known quantity of [14C]pyruvate in triplicate in parallel with experimental samples.

Linear fits (Lineweaver-Burke) and one-site saturation fits (Michaelis-Menten) were performed in SigmaPlot. Initial rates were calculated using a linear fit with either SigmaPlot or Microsoft Excel. Figures were prepared using Microsoft PowerPoint and SigmaPlot. Data were organized in Microsoft Excel, and statistical outliers were identified using the Grubbs’ test. Unless otherwise noted, data are represented as mean ± S.E.

Results

Our overall objectives were, first, to develop a method for measuring the MPC specific activity that enabled greater throughput with decreased sample requirements and, second, to test the efficacy of that method by determining the kinetics of the mouse liver mitochondrial MPC specific activity, which have not been reported previously. For these studies, intact, well coupled mouse liver mitochondria were required. We utilized a differential centrifugation protocol and buffers adapted from Rogers et al. (19) with the procedure summarized in Fig. 1A. Two quality control experiments were performed. First, succinate-driven respiration was measured using a Clark electrode. The resulting respiratory control ratio of 6.38 ± 0.24 (as shown in Fig. 1B) indicated that the isolated mitochondria robustly respire and were well coupled (21). Second, Western blotting analysis was performed on samples taken throughout the mitochondrial isolation procedure to gauge the overall purity of the mitochondrial isolations. The blots (shown in Fig. 1C) indicate that the final preparations were cytoplasm-free as shown by the marker HSP90 and contain only limited endoplasmic reticulum contamination as shown by the marker calreticulin (21, 22).

We reasoned that scaling the assay to a 96-well, multichannel pipette-compatible format and coupling the mitochondrial pyruvate uptake step to a 96-well vacuum manifold apparatus for washing and collecting postassay mitochondrial samples would simultaneously increase throughput while decreasing sample requirements. The use of the manifold, with required modifications in setup, is described in detail under “Experimental Procedures” and illustrated in Fig. 2. Primary considerations for manifold setup included prevention of vacuum leaks, effective washing and retention of mitochondrial samples, and an end point physical state of samples allowing easy transfer to scintillation vials for measuring 14C content. Wells not to be

---

FIGURE 1. Mitochondrial isolation and assessment of mitochondrial quality. A, flow chart illustrating the mitochondrial isolation procedure including branch points for separating mitochondria for oxygen consumption by Seahorse extracellular flux analyzer and pyruvate uptake determination. B, representative trace acquired by a Clark-type electrode monitoring oxygen consumption of isolated mitochondria. The respiratory control ratio (State III rate/State IV + oligomycin rate) is shown (n = 4). C, Western blotting analysis of samples taken throughout the isolation procedure showing the purification of mitochondrial proteins (Hsp90, cytosolic marker; calreticulin, endoplasmic reticulum marker; Pdh1a, mitochondrial matrix marker; Mpc1, inner mitochondrial membrane; Vdac, mitochondrial inner membrane marker). Sup, supernatant.
used for a particular assay were blocked using 96-well plate sealers as shown in Fig. 2A. The sealers can be easily removed and modified as needed to accommodate different and unique assay designs. An additional safeguard against leaks was implemented by tightly wrapping the outside of the assembled apparatus with Parafilm as shown in Fig. 2B.

To enable washing and retention of mitochondrial samples, we utilized a two-layer filter system with an upper layer of cellulose ester with 0.80-μm pores and an underlying layer of nitrocellulose with 0.45-μm pores. The larger pore size of the upper layer prevents clogging, and the smaller pore size of the lower layer prevents loss of minimal amounts of mitochondrial sample that pass through the upper layer. Because the washing step results in deposition of a mitochondrial disc on the filter layer, the final samples need not be perturbed prior to scintillation counting. Instead, the filter layer is cut into pieces for each mitochondrial disc as described under “Experimental Procedures” and used as a vehicle for transferring samples into scintillation vials for counting as shown in Fig. 2, E and F.

To test the efficacy of our method, mouse liver mitochondria were isolated, and a time course of the MPC specific activity was measured with pyruvate concentrations ranging from 0.001 to 0.200 mM. The collected data were used to calculate the MPC $V_{\text{max}}$ and $K_m$ of mouse liver mitochondria. The apparent linear phase of uptake is limited by a finite mitochondrial matrix volume. We observed that the uptake rate was near linear through 5–10 s with a rapid decrease in rate through 30 s, and our representative traces are shown in Fig. 3A. The initial rates through 5 s were determined and plotted against pyruvate concentration. The data were fitted to the Michaelis-Menten equation for determination of $K_m$ and $V_{\text{max}}$ values. The calculated $K_m$ and $V_{\text{max}}$ values for the mouse liver MPC specific activity were 28.0 ± 3.9 μM and 1.08 ± 0.05 nmol/min/mg of mitochondrial protein, respectively, as shown in Fig. 3, B and C.

Our observation that isolated mouse liver mitochondria display rapid uptake rates led us to investigate potential ways to extend the linear range of the assay. To increase the length of the initial linear phase of uptake, we pretreated mitochondria with a nanomolar amount of the potassium ionophore valinomycin (see Fig. 5A). Potassium transported by valinomycin at this concentration (3 nM) results in matrix swelling without rupturing the outer mitochondrial membrane (23). Although the linear range for the assay was increased, allowing for the calculation of initial rates through 10 s, valinomycin...
cin did not statistically change the $K_m$ of mouse liver MPC (see Fig. 5, B and C).

To enable efficient use of biological samples, we designed our mitochondrial pyruvate uptake assay to be compatible with sample partitioning for parallel measurements of pyruvate oxidation. During the mitochondrial isolation, small fractions may be centrifuged separately for measurements of additional mitochondrial parameters as represented in Fig. 1A. For example, whereas the majority of mitochondria are required for the uptake assay, aliquots can be taken for other measures of mito-
Multiplexed Measurement of MPC Activity

Pyruvate uptake directly measures the transport of pyruvate across the mitochondrial inner membrane by the activity of the MPC. Although MPC activity is required for mitochondrial

Discussion

The recent discovery of the genes encoding the MPC (1, 2) has invigorated studies on the role of mitochondrial pyruvate transport and metabolism in health and disease. To facilitate these studies, we developed a mitochondrial pyruvate uptake assay with minimal sample requirements. The use of a 96-well vacuum blot apparatus allows for rapid and multiplexed analysis of radiolabeled pyruvate uptake in isolated mitochondria. The increased throughput of a multiwell system allows for the parallel analysis of replicates, either biological or technical, and therefore greater uniformity in sample processing and more confident quantitative analysis. This technique allows for pyruvate uptake to be determined in multiple unique mitochondrial preparations over the course of a few hours.

Previous determinations of MPC kinetics have been pursued in diverse model systems including mitochondria isolated from rat liver, rat heart muscle, and cultured cells. To compare our MPC kinetic data with previously obtained data, we performed a survey of the published MPC \( K_m \) and \( V_{max} \) values across multiple species and uptake methods, which are compiled in Table 1. MPC activity requires a proton-motive force because pyruvate import through the MPC requires co-proton import (18, 24). The wide range of MPC activity values may be attributed to several factors. First, the source of the isolated mitochondria being assayed, species and tissues, could have unique characteristics that contribute to the variability. Second, the temperatures at which the assays were performed, from room temperature down to 4 °C, directly affect MPC specific activity. Third, the source of protons required for co-transport could also contribute to differences in observed MPC \( K_m \) and \( V_{max} \) values. For example, the driving force provided by ascorbate/TMPD is dependent on the integrity of the electron transport chain and is limited to mitochondrial-intrinsic generation of a proton-motive force. Furthermore, temperature also affects the rate of electron transfer from Complex IV to O\(_2\) and thus generation of a proton-motive force. In contrast, generating a differential pH by diluting mitochondria into an experimental buffer system of a lower pH, as was done here, saturates the pool of protons available for co-transport with pyruvate independently of temperature. Finally, \( K_m \) and \( V_{max} \) values are calculated from initial rates, which are corrected for the amount of total mitochondrial protein used in the assays. The absolute amount of MPC protein will vary depending upon the mitochondrial source and the conditions being examined. Furthermore, investigation of MPC activity in intact mitochondrial preparations required normalization to mitochondrial protein content. Given the multitude of experimental approaches, it is not surprising to see variance in reported \( K_m \) and \( V_{max} \) values.

The most direct comparison with our present results can be made to a study that was conducted at a similar temperature and utilized a pH gradient to drive uptake (18). This previous study, using isolated rat liver mitochondria, reported a \( K_m \) of 150 ± 20 \( \mu \)mol, which is ~5.4- and ~2.1-fold less specific than the \( K_m \) values we measured here for mouse and rat liver mitochondria, respectively. Furthermore, this previous report determined a \( V_{max} \) of 0.54 ± 0.03 nmol/min/mg of mitochondrial protein, which is ~2-fold slower for mouse and ~2.6-fold slower for rat compared with our calculated values. The differences observed between mouse and rat liver MPC activity may reflect the comparatively greater basal metabolic rate of the mouse.

The recent discovery of the genes encoding the MPC (1, 2) has invigorated studies on the role of mitochondrial pyruvate transport and metabolism in health and disease. To facilitate these studies, we developed a mitochondrial pyruvate uptake assay with minimal sample requirements. The use of a 96-well vacuum blot apparatus allows for rapid and multiplexed analysis of radiolabeled pyruvate uptake in isolated mitochondria. The increased throughput of a multiwell system allows for the parallel analysis of replicates, either biological or technical, and therefore greater uniformity in sample processing and more confident quantitative analysis. This technique allows for pyruvate uptake to be determined in multiple unique mitochondrial preparations over the course of a few hours.

Previous determinations of MPC kinetics have been pursued in diverse model systems including mitochondria isolated from rat liver, rat heart muscle, and cultured cells. To compare our MPC kinetic data with previously obtained data, we performed a survey of the published MPC \( K_m \) and \( V_{max} \) values across multiple species and uptake methods, which are compiled in Table 1. MPC activity requires a proton-motive force because pyruvate import through the MPC requires co-proton import (18, 24). The wide range of MPC activity values may be attributed to several factors. First, the source of the isolated mitochondria being assayed, species and tissues, could have unique characteristics that contribute to the variability. Second, the temperatures at which the assays were performed, from room temperature down to 4 °C, directly affect MPC specific activity. Third, the source of protons required for co-transport could also contribute to differences in observed MPC \( K_m \) and \( V_{max} \) values. For example, the driving force provided by ascorbate/TMPD is dependent on the integrity of the electron transport chain and is limited to mitochondrial-intrinsic generation of a proton-motive force. Furthermore, temperature also affects the rate of electron transfer from Complex IV to O\(_2\) and thus generation of a proton-motive force. In contrast, generating a differential pH by diluting mitochondria into an experimental buffer system of a lower pH, as was done here, saturates the pool of protons available for co-transport with pyruvate independently of temperature. Finally, \( K_m \) and \( V_{max} \) values are calculated from initial rates, which are corrected for the amount of total mitochondrial protein used in the assays. The absolute amount of MPC protein will vary depending upon the mitochondrial source and the conditions being examined. Furthermore, investigation of MPC activity in intact mitochondrial preparations required normalization to mitochondrial protein content. Given the multitude of experimental approaches, it is not surprising to see variance in reported \( K_m \) and \( V_{max} \) values.

The most direct comparison with our present results can be made to a study that was conducted at a similar temperature and utilized a pH gradient to drive uptake (18). This previous study, using isolated rat liver mitochondria, reported a \( K_m \) of 150 ± 20 \( \mu \)mol, which is ~5.4- and ~2.1-fold less specific than the \( K_m \) values we measured here for mouse and rat liver mitochondria, respectively. Furthermore, this previous report determined a \( V_{max} \) of 0.54 ± 0.03 nmol/min/mg of mitochondrial protein, which is ~2-fold slower for mouse and ~2.6-fold slower for rat compared with our calculated values. The differences observed between mouse and rat liver MPC activity may reflect the comparatively greater basal metabolic rate of the mouse.

Pyruvate uptake directly measures the transport of pyruvate across the mitochondrial inner membrane by the activity of the MPC. Although MPC activity is required for mitochondrial
Multiplexed Measurement of MPC Activity

TABLE 1

Reported $K_m$ and $V_{max}$ values for the MPC

| Tissue of origin | Proton-motive force | Temperature °C | $K_m$ μM | $V_{max}$ mmol/min/mg | Sample size | Ref. |
|------------------|---------------------|---------------|----------|-----------------------|-------------|------|
| Rat heart (young) | Ascorbate/TMPD      | 10            | 210 ± 15 | 6.8 ± 0.7             | n = 5 experiments | 25   |
| Rat heart (old)   | Ascorbate/TMPD      | 10            | 222 ± 23 | 4.2 ± 0.5             | n = 5 experiments | 25   |
| Rat liver         | ΔpH                 | 6             | 150 ± 20 | 0.54 ± 0.03           | n = 15 observations | 18   |
| Rat liver (control) | Ascorbate/TMPD | RT            | 840 ± 90 | 43.1 ± 3.8            | n = 4 experiments | 26   |
| Rat liver (glucagon) | Ascorbate/TMPD | RT            | 1170 ± 130 | 74.83 ± 1.99 | n = 4 experiments | 26   |
| Rat liver         | Ascorbate/TMPD      | RT            | 27.52 ± 1.55 | 119 ± 1.72 | n = 19 experiments | 27   |
| Rat liver         | Passive uptake      | 20            | 640 ± 10 | 19.8 ± 0.5            | n = 4–6       | 28   |
| Ehrlich ascites   | Passive uptake      | 20            | 643 ± 20 | 11.8 ± 0.6            | n = 4–6       | 28   |
| Morris 44 hepatoma | Passive uptake      | 20            | 740 ± 30 | 11.6 ± 0.8            | n = 4–6       | 28   |
| Morris 324A hepatoma | Passive uptake | 20            | 1100 ± 70 | 4.7 ± 0.5   | n = 4–6       | 28   |
| Mouse liver       | ΔpH                 | 4             | 28.0 ± 3.9 | 1.08 ± 0.05        | n = 3–10 (per concentration) | This report |
| Mouse liver (valinomycin) | ΔpH | 4             | 20.3 ± 7 | 0.75 ± 0.08         | n = 4–9 (per concentration) | This report |
| Rat liver         | ΔpH                 | 4             | 71.2 ± 17 | 1.42 ± 0.14          | n = 5 (per concentration) | This report |

Pyruvate oxidation, these processes are not always coupled 1:1. Upon MPC-dependent uptake, pyruvate can be carboxylated to oxaloacetate by pyruvate carboxylase, oxidized to acetyl-CoA by the pyruvate dehydrogenase complex, or transaminated to alanine by alanine aminotransferase 2. Monitoring pyruvate oxidation effectively observes the activity of the pyruvate dehydrogenase complex wherein NADH is produced and then oxidized by Complex I for electron transport. As such, pyruvate oxidation only observes one branch of intramitochondrial pyruvate metabolism and is not coupled to relative MPC activity. As shown above, MPC specific activity was not different between the fed and fasted liver mitochondria when measured by radiolabeled pyruvate uptake assays. However, significant differences were observed when pyruvate oxidation was assessed in the same mitochondrial preparations. This illustrates the importance of measuring the MPC specific activity directly as a distinct biochemical parameter rather than relying upon pyruvate oxidation as a surrogate measurement.

We expect our assay will be complementary to developing technologies for measuring metabolite flux in living cells. Recently, MPC1 and MPC2 constructs were genetically encoded with C-terminal tags that together form a bioluminescent resonance energy transfer system. Conformational changes in the MPC when transporting pyruvate bring the C-terminal tags into close proximity, allowing for specific emission of light from the excited fluorophore (6). Importantly, MPC flux in vivo is a compound parameter that is affected by the MPC specific activity, intramitochondrial pyruvate metabolism, and cellular pyruvate metabolism. Thus, measurements of MPC flux do not resolve the MPC specific biochemical activity. Accordingly, the radiolabeled pyruvate uptake assay persists as a fundamental assay to observe the kinetics of the MPC specific activity.

The focus of this report has been to describe a novel method for measuring pyruvate uptake by mitochondria isolated from animal liver. We expect this method will be useful for additional applications because the material and pore size of the filters can be changed to be compatible with other kinds of samples. As an example, we expect it could be adapted for measurements of MPC activity in permeabilized, cultured cells after testing for filter combinations that retain sample but are not clogged. Furthermore, we expect the scalability of our method could enable mitochondria isolated from cultured cells and liposomes reconstructed with purified transporter to be assayed in a similar manner. Finally, we propose that this method will be useful for measuring mitochondrial uptake of metabolites beyond pyruvate where a radiolabeled form and a chemical inhibitor are available.

In conclusion, we illustrate a 96-well scaled method to assay MPC-dependent pyruvate uptake into isolated mitochondria. Smaller sample requirements coupled to multiplexed processing markedly increased throughput compared with previously reported methods. We applied this method to measure and provide the first report on the $K_m$ and $V_{max}$ of the mouse liver MPC activity. We expect this method will be of value for understanding the contribution of the MPC activity to health and disease states where pyruvate metabolism is expected to play a prominent role.

**Author Contributions**—L. R. G., A. J. R., and E. B. T. designed the assays, analyzed the results, and wrote the manuscript.

**Acknowledgments**—We thank Brett Wagner and the Radiation and Free Radical Research Facility for help running the experiments utilizing the Seahorse Bioscience XF96 analyzer. We also thank the University of Iowa’s Creative Media Group and the photography services of Susan McCellen, who produced the photographs utilized in Fig. 2.

**References**

1. Bricker, D. K., Taylor, E. B., Schell, J. C., Orsak, T., Boutron, A., Chen, Y. C., Cox, J. E., Cardon, C. M., Van Vranken, J. G., Dephoure, N., Redin, C., Boudina, S., Gygi, S. P., Brivet, M., Thummel, C. S., and Rutter, J. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, *Drosophila*, and humans. *Science* 337, 96–100
2. Herzig, S., Raeny, E., Montessuit, S., Veuthey, J. L., Zamboni, N., Westermann, B., Kunji, E. R., and Martinou, J. C. (2012) Identification and functional expression of the mitochondrial pyruvate carrier. *Science* 337, 93–96
3. Gray, L. R., Tompkins, S. C., and Taylor, E. B. (2014) Regulation of pyruvate metabolism and human disease. *Cell. Mol. Life Sci.* 71, 2577–2604
4. Saudek, V. (2012) Cystinosin, MDU1, SWEETs and KDEL belong to a well-defined protein family with putative function of cargo receptors involved in vesicle trafficking. *PLoS One* 7, e30876
5. Bender, T., Pena, G., and Martinou, J. C. (2015) Regulation of mitochondrial pyruvate uptake by alternative pyruvate carrier complexes. *EMBO J.* 34, 911–924
6. Compan, V., Pierreodon, S., Vanderperre, B., Krznar, P., Marchi, I., Zamboni, N., Pouysségur, J., and Martinou, J. C. (2015) Monitoring mitochondrial pyruvate carrier activity in real time using a BRET-based biosensor:
Multiplexed Measurement of MPC Activity

inhibited by valproic acid and metabolites in mitochondrial membranes. FEBS Lett. 582, 3359–3366

17. Angaman, D. M., Petrizzo, R., Hernández-Gras, F., Romero-Segura, C., Pateraki, I., Busquets, M., and Boronat, A. (2012) Precursor uptake assays and metabolic analyses in isolated tomato fruit chromoplasts. Plant Methods 8, 1

18. Halestrap, A. P. (1975) The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem. J. 148, 85–96

19. Rogers, G. W., Brand, M. D., Petrosyan, S., Ashok, D., Elorza, A. A., Ferrick, D. A., and Murphy, A. N. (2011) High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLoS One 6, e21746

20. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254

21. Fernández-Vizarra, E., López-Pérez, M. J., and Enríquez, J. A. (2002) Isolation of biogenetically competent mitochondria from mammalian tissues and cultured cells. Methods 26, 292–297

22. Fernández-Vizarra, E., Ferrín, G., Pérez-Martos, A., Fernández-Silva, P., Zeviani, M., and Enríquez, J. A. (2010) Isolation of mitochondria for biogenetical studies: an update. Mitochondrion 10, 253–262

23. Gogvadze, V., Orrenius, S., and Zhivotovsky, B. (2006) Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim. Biophys. Acta 1757, 639–647

24. Papa, S., Francavilla, A., Paradies, G., and Meduri, B. (1971) The transport of pyruvate in rat liver mitochondria. FEBS Lett. 12, 285–288

25. Paradies, G., and Ruggiero, F. M. (1990) Age-related changes in the activity of the pyruvate carrier and in the lipid composition in rat-heart mitochondria. Biochim. Biophys. Acta 1016, 207–212

26. Titheradge, M. A., and Coore, H. G. (1976) The mitochondrial pyruvate carrier, its exchange properties and its regulation by glucagon. FEBS Lett. 85–96

27. Titheradge, M. A., and Coore, H. G. (1975) Initial rates of pyruvate transport in mitochondria determined by an "inhibitor-stop" technique. Biochem. J. 150, 553–556

28. Paradies, G., Capuano, F., Palombini, G., Galeotti, T., and Papa, S. (1983) Transport of pyruvate in mitochondria from different tumor cells. Cancer Res. 43, 5068–5071